全文获取类型
收费全文 | 888篇 |
免费 | 79篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 16篇 |
妇产科学 | 14篇 |
基础医学 | 146篇 |
口腔科学 | 6篇 |
临床医学 | 80篇 |
内科学 | 216篇 |
皮肤病学 | 26篇 |
神经病学 | 93篇 |
特种医学 | 18篇 |
外国民族医学 | 2篇 |
外科学 | 120篇 |
综合类 | 2篇 |
预防医学 | 39篇 |
眼科学 | 30篇 |
药学 | 52篇 |
中国医学 | 2篇 |
肿瘤学 | 102篇 |
出版年
2024年 | 2篇 |
2023年 | 13篇 |
2022年 | 10篇 |
2021年 | 43篇 |
2020年 | 20篇 |
2019年 | 30篇 |
2018年 | 43篇 |
2017年 | 28篇 |
2016年 | 34篇 |
2015年 | 41篇 |
2014年 | 32篇 |
2013年 | 44篇 |
2012年 | 77篇 |
2011年 | 86篇 |
2010年 | 42篇 |
2009年 | 42篇 |
2008年 | 58篇 |
2007年 | 67篇 |
2006年 | 42篇 |
2005年 | 33篇 |
2004年 | 31篇 |
2003年 | 29篇 |
2002年 | 27篇 |
2001年 | 7篇 |
2000年 | 17篇 |
1999年 | 10篇 |
1998年 | 7篇 |
1997年 | 5篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1994年 | 2篇 |
1992年 | 11篇 |
1991年 | 6篇 |
1990年 | 8篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1987年 | 2篇 |
1986年 | 3篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1974年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有970条查询结果,搜索用时 750 毫秒
11.
12.
13.
14.
15.
Sprague Rebecca Warny Karolyne Pollock Nira Daugherty Kaitlyn Lin Qianyun Xu Hua Cuddemi Christine Barrett Caitlin Chen Xinhua Banz Alice Lantz Aude Garey Kevin W. Gonzales-Luna Anne J. Alonso Carolyn D. Galvez Javier A. Villafuerte Kelly Ciarán P. 《Digestive diseases and sciences》2021,66(10):3303-3306
Digestive Diseases and Sciences - Clostridioides difficile infection (CDI) is caused by Toxins A and B, secreted from pathogenic strains of C. difficle. This infection can vary greatly in symptom... 相似文献
16.
Mignot A Bridoux F Thierry A Varnous S Pujo M Delcourt A Gombert JM Goujon JM Favreau F Touchard G Herpin D Jaccard A 《Haematologica》2008,93(3):e32-e35
Recurrence in the allograft and progression in other organs increase mortality after cardiac transplantation in AL amyloidosis. Survival may be improved after suppression of monoclonal light chain (LC) production following high dose melphalan and autologous stem cell transplantation (HDM/ASCT). However, because of high treatment related mortality, this tandem approach is restricted to few patients without significant extra-cardiac involvement. A diagnosis of systemic AL amyloidosis was established in a 45-year old patient with congestive heart failure related to restrictive cardiomyopathy, nephrotic syndrome, peripheral neuropathy, postural hypotension, macroglossia, and lambda LC monoclonal gammopathy. After melphalan and dexamethasone (M-Dex) therapy, which resulted in 80% reduction of serum free lambda LC, he underwent orthotopic cardiac transplantation. Two years later, he remains in a sustained hematologic remission, with no evidence of allograft or extra-cardiac amyloid accumulation. M-Dex should be considered as an alternative therapy in AL amyloid heart transplant recipients ineligible for HDM/ASCT. 相似文献
17.
18.
19.
Michallet M Thomas X Vernant JP Kuentz M Socié G Espérou-Bourdeau H Milpied N Blaise D Rio B Reiffers J Jouet JP Cahn JY Bourhis JH Lioure B Leporrier M Sotto JJ Souillet G Sutton L Bordigoni P Dreyfus F Tilly H Gratecos N Attal M Leprise PY Déméocq F Michel G Buzyn A Delmas-Marsalet B Bernaudin F Ifrah N Sadoun A Guyotat D Cavazzana-Cavo M Caillot D De Revel T Vannier JP Baruchel A Fegueux N Tanguy ML Thiébaut A Belhabri A Archimbaud E 《Bone marrow transplantation》2000,26(11):1157-1163
To assess the place of allogeneic hematopoietic stem cell transplantation (HSCT) in the advanced stage of acute myeloid leukemia (AML), we retrospectively analyzed 379 consecutive patients who underwent allogeneic HSCT for advanced AML. The median follow-up of the entire cohort was 7.5 years. Sixty-nine patients (18%) were transplanted with primary resistant disease. Three hundred and ten (82%) were relapsed patients, 94 (30%) of whom were in untreated relapse, 67 (22%) in refractory relapse and 149 (48%) in 2nd or 3rd complete remission at time of transplantation. The 5-year probabilities of overall survival (OS), disease-free survival (DFS), and transplant-related mortality (TRM) were 22 +/- 4%, 20 +/- 4%, 45 +/- 6%, respectively. In multivariate analysis, we demonstrated the favorable impact on OS, DFS and TRM of two factors over which we have no control (age <15 years, complete remission achievement) and three factors over which we have some control (female donor, acute and chronic graft-versus-host disease). The results of this study suggest that the graft-versus-leukemia effect is important in advanced AML and that new HSCT modalities are needed for some patients with this indication. 相似文献
20.
Solary E; Witz B; Caillot D; Moreau P; Desablens B; Cahn JY; Sadoun A; Pignon B; Berthou C; Maloisel F; Guyotat D; Casassus P; Ifrah N; Lamy Y; Audhuy B; Colombat P; Harousseau JL 《Blood》1996,88(4):1198-1205
A phase III prospective randomized multicenter study was performed to determine whether quinine could improve the response rate of poor-risk acute leukemias (ALs) to standard chemotherapy including a multidrug resistance (MDR)-related cytotoxic agent. The rationale of the study was based on the negative prognostic value of MDR phenotype in ALs and the ability of quinine to reverse this phenotype both in vitro and ex vivo. Three hundred fifteen patients (median age, 49 years; range, 16 to 65) with relapsed (n = 108) or refractory (n = 32) acute myeloblastic leukemia (AML), relapsed (n = 27) or refractory (n = 9) acute lymphoblastic leukemia (ALL), secondary AL (n = 22) or blastic transformation of myelodysplastic syndrome ([MDS] n = 74) or myeloproliferative syndrome ([MPS] n = 43) were randomly assigned to receive mitoxantrone ([MXN] 12 mg/m2/d, days 2 to 5) and cytarabine ([Ara-C] 1 g/m2/12 h, days 1 to 5) alone or in combination with quinine (30 mg/kg/d, days 1 to 5; continuous intravenous infusion beginning 24 hours before MXN infusion). Side effects of quinine were observed in 56 of 161 quinine-treated patients and disappeared in all but four cases after one or two 20% dose decreases. Sera from quinine-treated patients showed increased MXN uptake in an MDR-positive cell line compared with matched sera obtained before quinine infusion. Quinine induced a significant increase in the incidence of nausea, vomiting, mucositis, and cardiac toxicity. A complete response (CR) was observed in 85 of 161 patients (52.8%) from the quinine-treated group versus 70 of 154 patients (45.5%) in the control group (P = .19). The most important differences between quinine and control group CR rates were observed in patients with refractory AMLs and blastic transformation of MDS and MPS. The CR rate was higher in P-glycoprotein-positive cases, although the difference was not significant. Failure of the regimen due to blastic persistence or blast number increase was higher in the control group (61 of 154 patients) than in the quinine group (45 of 161, P = .04). Early death was observed in eight cases (four in each arm) and death in aplasia in 27 cases (20 in quinine group v seven in control group, P = .01). The significant increase of toxicity in the quinine arm could have masked the clinical benefit of MDR reversion in poor- risk ALs. 相似文献